Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's DiseaseStephen Salloway, H. Robert Brashear, Reisa A. Sperling et al.|New England Journal of Medicine|2014Cited by 2k
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisReisa A. Sperling, Michael Grundman, Stephen Salloway et al.|The Lancet Neurology|2012Cited by 510
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled TrialPaula K. Schweitzer, Kingman P. Strohl, Russell Rosenberg et al.|American Journal of Respiratory and Critical Care Medicine|2018Cited by 316
Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trialsEnchi Liu, Arthur Spirling, Mark E. Schmidt et al.|Neurology|2015Cited by 152
MR Imaging Features of Amyloid-Related Imaging AbnormalitiesJerome Barakos, Michael Grundman, Stephen Salloway et al.|American Journal of Neuroradiology|2013Cited by 111